Sakar Healthcare Limited has informed the Exchange regarding Appointment of Mr Raviraj Karia as Senior Vice President (Finance & Accounts) of the company w.e.f. July 25, 2025.
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sakar Healthcare's board, which met on July 25, 2025, approved the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025) along with the auditor's limited review report. The 21st Annual General Meeting was scheduled for September 23, 2025, via video conferencing, with remote e-voting open from September 20 to September 22, 2025. Three new Independent Directors — Ms. Megha Samdani, Ms. Reeya Kothari, and Ms. Hiral Patel — were appointed for five-year terms, subject to shareholder approval. New secretarial auditors (M/s. Nishant Pandya & Associates, for FY26–FY30) and cost auditors (M/s. Dalwadi & Associates, for FY26) were also recommended/appointed.
The appointments strengthen the board and senior management with experienced pharma and finance professionals, which is generally viewed positively. Routine in nature and unlikely to cause immediate stock price movement, though investors should watch the Q1 FY26 results for actual business performance.